Cordycepin

Confirm delete?

Cordycepin

Zoom

Cat No: 14426

Biochemicals - Small Molecule Inhibitors

Cordycepin is a nucleoside analog found in C. sinensis that acts as a polyadenylation inhibitor when converted to cordycepin triphosphate, which inhibits ATP-dependent DNA and RNA synthesis.{22954} Cordycepin has a broad spectrum of biological activit...

This product can only be bought through Cayman Chemical. Please contact us.

Product Overview
Data
Downloads
About Cayman

Territorial Availability: Available through Bertin Technologies only in France

Synonyms:

3'-deoxy-adenosine

Correlated keywords:

153-49-1 48171-89-7 nucleosides analogs 3’-deoxyadenosine polyadenylation inhibitors inhibits inhibitions DNA deoxyribonucleic acids ribonucleic synthesis RNA synthesis anti-proliferative pro-apoptotic anti-inflammatory antiproliferative anti proliferative proapoptotic pro apoptotic inflammatory antiinflammatory sinensis 3’-dATP NSCs NSC-401022 NSC-63984 NSC401022 NSC63984 anti-inflammatories cordyceps triphosphates ATP-dependent biological poly A tails mRNA length activates AMPK kinases mTOR signals signaling

Product Overview:
Cordycepin is a nucleoside analog found in C. sinensis that acts as a polyadenylation inhibitor when converted to cordycepin triphosphate, which inhibits ATP-dependent DNA and RNA synthesis.{22954} Cordycepin has a broad spectrum of biological activities, including anti-proliferative, pro-apoptotic, and anti-inflammatory effects.{22954,22953,22955} Cordycepin has been shown to reduce poly(A) tail length in mRNA at 10 μM and to activate AMPK kinase, leading to a reduction in mTOR signaling at 200 μM.{22954}

Size	10 mg
Shipping	dry ice
CAS Number	73-03-0
Molecular Formula	C₁₀H₁₃N₅O₃
SMILES	OC[C@@H]1C[C@@H](O)[C@H](N2C=NC3=C2N=CN=C3N)O1
Molecular Weight	251,2
Formulation	A crystalline solid
Purity	≥98%
Custom Code	2922.19
UNSPSC code	12352100

Technical File

MSDS

Click here to ask for your quote and get 15% off Cayman's products.

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.